Why is Cardiff Oncology stock surging today?
Cardiff Oncology (CRDF) stock rose 25% after FDA granted Fast Track designation to onvansertib for treating KRAS- or NRAS-mutated metastatic colorectal cancer. The designation is based on Phase 2 trial data showing a 72.2% response rate. CEO Mani Mohindru is presenting at the UBS Global Biopharma Conference. The stock's surge contrasts with a broader market decline.
